Zealand Pharma A/S
ZEAL.CO · CPH
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.44 | 0.74 | 0.80 | -0.80 |
| FCF Yield | -1.99% | -2.13% | -10.25% | -19.84% |
| EV / EBITDA | -46.67 | -31.91 | -9.81 | -8.06 |
| Quality | ||||
| ROIC | -13.87% | -33.18% | -59.69% | -59.56% |
| Gross Margin | 87.44% | 94.41% | 70.47% | 59.39% |
| Cash Conversion Ratio | 0.86 | 0.60 | 0.78 | 1.19 |
| Growth | ||||
| Revenue 3-Year CAGR | -15.52% | 5.42% | -33.48% | 92.00% |
| Free Cash Flow Growth | -110.04% | 52.89% | 22.70% | -72.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 0.51 | 0.71 | 0.47 |
| Interest Coverage | -31.11 | -19.75 | -14.46 | -256.71 |
| Efficiency | ||||
| Inventory Turnover | 0.74 | 2.42 | 23.88 | 1.00 |
| Cash Conversion Cycle | -7,098.16 | -1,462.51 | -1,651.41 | -263.07 |